LV5FU2 with high-dose leucovorin (LV), weekly infusional 5-fluorouracil (5FU) (AIO schedule) and raltitrexed have been demonstrated to be active agents in first-line treatment of colorectal cancer. We performed a 4-arm randomised trial to compare (1) a low-dose intravenous bolus of LV (20 mg/m2), followed by an intravenous bolus of 5FU (400 mg/m2), followed by a 22-hour continuous infusion of 5FU (600 mg/m2) on day 1 and day 2/2 weeks (ldLV5FU2 arm), (2) a weekly continuous infusion of high-dose 5FU (2.6 g/m2/week) for 6 weeks followed by a rest week (HD-FU arm) and (3) raltitrexed (Tomudex® arm; 3 mg/m2/3 weeks) to standard LV5FU2. From 1997 to 2001, 294 patients were included. The 4 arms were well balanced for sex ratio, age, WHO performance status, the primary tumour site and prior adjuvant chemotherapy. Treatment was stopped due to low accrual. Two toxicity-related deaths were observed in the Tomudex arm. The treatments gave rise to different rates of grade 3–4 neutropenia (3, 4, 11 and 14% of the patients in the LV5FU2, ldLV5FU2, HD-FU and Tomudex arms, respectively, p = 0.028), leucopenia and vomiting. At least one episode of grade 3–4 toxicity was observed in 27, 25, 38 and 47% of the patients in the LV5FU2, ldLV5FU2, HD-FU and Tomudex arms, respectively (p = 0.016). An objective response was observed in 28, 21, 22 and 10% of the patients in the LV5FU2, ldLV5FU2, HD-FU and Tomudex arms, respectively (p = 0.04). Progression-free survival (PFS) of the patients in the Tomudex arm was statistically lower compared to that of patients treated with LV5FU2 or ldLV5FU2 (combined group; p = 0.013, log rank test). In conclusion, Tomudex is more toxic and yields shorter PFS than infusional 5FU. Despite the early closure of the study and the lack of power of the comparison, it seems that ldLV5FU2 could be considered as an active, easier and less expensive option for the treatment of metastatic colorectal cancer compared to classic LV5FU2 or weekly HD-FU.

Keywords:
Colorectal cancer, 5-Fluorouracil, Raltitrexed, Leucovorin, Continuous infusion
1.
Parkin DM, Muir CS: Cancer incidence in five continents. Comparability and quality of data. IARC Sci Publ 1992;45–173.
2.
Parkin DM, Pisani P, Ferlay J: Estimates of the worldwide incidence of 25 major cancers in 1990. Int J Cancer 1999;80:827–841.
3.
Remontet L, Esteve J, Bouvier AM, Grosclaude P, Launoy G, Menegoz F, Exbrayat C, Tretare B, Carli PM, Guizard AV, Troussard X, Bercelli P, Colonna M, Halna JM, Hedelin G, Mace-Lesec’h J, Peng J, Buemi A, Velten M, Jougla E, Arveux P, Le Bodic L, Michel E, Sauvage M, Schvartz C, Faivre J: Cancer incidence and mortality in France over the period 1978–2000. Rev Epidemiol Sante Publique 2003;51:3–30.
4.
Sant M, Aareleid T, Berrino F, Bielska LM, Carli PM, Faivre J, Grosclaude P, Hedelin G, Matsuda T, Moller H, Moller T, Verdecchia A, Capocaccia R, Gatta G, Micheli A, Santaquilani M, Roazzi P, Lisi D: EUROCARE-3: survival of cancer patients diagnosed 1990–94 – Results and commentary. Ann Oncol 2003;14(suppl 5):V61–V118.
5.
Lokich J, Chawla PL, Brooks J, Frei E: Chemotherapy in pancreatic carcinoma: 5 fluorouracil (5FU) and 1,3 bis-(2 chloroethyl)-1-nitrosourea (BCNU). Ann Surg 1974;179:450–456.
6.
Lokich JJ, Ahlgren JD, Cantrell J, Heim WJ, Wampler GL, Gullo JJ, Fryer JG, Alt DE: A prospective randomized comparison of protracted infusional 5-fluorouracil with or without weekly bolus cisplatin in metastatic colorectal carcinoma. A Mid-Atlantic Oncology Program study. Cancer 1991;67:14–19.
7.
Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer. Meta-Analysis Group in Cancer. J Clin Oncol 1998;16:301–308.
8.
De Gramont A, Bosset JF, Milan C, Rougier P, Bouche O, Etienne PL, Morvan F, Louvet C, Guillot T, Francois E, Bedenne L: Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: a French intergroup study. J Clin Oncol 1997;15:808–815.
9.
Kohne CH, Wilke H, Hecker H, Schoffski P, Kaufer C, Rauschecker H, Andreesen R, Ohl U, Lange HJ, Klaassen U, et al: Interferon-alpha does not improve the antineoplastic efficacy of high-dose infusional 5-fluorouracil plus folinic acid in advanced colorectal cancer. First results of a randomized multicenter study by the Association of Medical Oncology of the German Cancer Society (AIO). Ann Oncol 1995;6:461–466.
10.
Kohne CH, Wils J, Lorenz M, Schoffski P, Voigtmann R, Bokemeyer C, Lutz M, Kleeberg C, Ridwelski K, Souchon R, El Serafi M, Weiss U, Burkhard O, Ruckle H, Lichnitser M, Langenbuch T, Scheithauer W, Baron B, Couvreur ML, Schmoll HJ: Randomized phase III study of high-dose fluorouracil given as a weekly 24-hour infusion with or without leucovorin versus bolus fluorouracil plus leucovorin in advanced colorectal cancer: European organization of Research and Treatment of Cancer Gastrointestinal Group Study 40952. J Clin Oncol 2003;21:3721–3728.
11.
Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: evidence in terms of response rate. Advanced Colorectal Cancer Meta-Analysis Project. J Clin Oncol 1992;10:896–903.
12.
Labianca R, Cascinu S, Frontini L, Barni S, Fiorentini G, Comella G, Zaniboni A, Gottardi O, Arnoldi E, Oliani C, Duro M, Pavanato G, Martignoni G, Raina A, Piazza E, Dallavalle G, Valsecchi R, Pancera G, Luporini G: High- versus low-dose levo-leucovorin as a modulator of 5-fluorouracil in advanced colorectal cancer: a ‘GISCAD’ phase III study. Italian Group for the Study of Digestive Tract Cancer. Ann Oncol 1997;8:169–174.
13.
Poon MA, O’Connell MJ, Moertel CG, Wieand HS, Cullinan SA, Everson LK, Krook JE, Mailliard JA, Laurie JA, Tschetter LK, et al: Biochemical modulation of fluorouracil: evidence of significant improvement of survival and quality of life in patients with advanced colorectal carcinoma. J Clin Oncol 1989;7:1407–1418.
14.
Poon MA, O’Connell MJ, Wieand HS, Krook JE, Gerstner JB, Tschetter LK, Levitt R, Kardinal CG, Mailliard JA: Biochemical modulation of fluorouracil with leucovorin: confirmatory evidence of improved therapeutic efficacy in advanced colorectal cancer. J Clin Oncol 1991;9:1967–1972.
15.
Cunningham D: Mature results from three large controlled studies with raltitrexed (‘Tomudex’). Br J Cancer 1998;77(suppl 2): 15–21.
16.
Maughan TS, James RD, Kerr D, McArdle C, Ledermann JA, Seymour M, Johnston C, Stephens RJ: Preliminary results of a multicentre randomised trial comparing 3 chemotherapy regimens (de Gramont, Lokich and raltitrexed) in metastatic colorectal cancer. Proc Am Soc Clin Oncol 1999;18:263a.
17.
Maughan TS, James RD, Kerr DJ, Ledermann JA, McArdle C, Seymour MT, Cohen D, Hopwood P, Johnston C, Stephens RJ: Comparison of survival, palliation, and quality of life with three chemotherapy regimens in metastatic colorectal cancer: a multicentre randomised trial. Lancet 2002;359:1555–1563.
18.
World Health Organization: WHO Handbook for Reporting Results of Cancer Treatment. Geneva, World Health Organization, 1979.
19.
Schaid DJ, Wieand HS, Therneau TM: Optimal tow-stage screening designs for survival comparison. Biometrika 1990;77:507–514.
20.
Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, Filiberti A, Flechtner H, Fleishman SB, de Haes JC: The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 1993;85:365–376.
21.
Cunningham D, Zalcberg JR, Rath U, Olver I, Van Cutsem E, Svensson C, Seitz JF, Harper P, Kerr D, Perez-Manga G, et al: ‘Tomudex’ (ZD1694): results of a randomised trial in advanced colorectal cancer demonstrate efficacy and reduced mucositis and leucopenia. The ‘Tomudex’ Colorectal Cancer Study Group. Eur J Cancer 1995;31A:1945–1954.
22.
Cocconi G: Results of a European multicentre trial of Tomudex versus 5-FU/high dose LV (Machover regimen). Tumori 1997;83:S72.
23.
Pazdur R, Vincent M: Raltitrexed (Tomudex®) versus 5-fluorouracil and leucovorin (5FU + LV) in patients with advanced colorectal cancer (ACC): results of a randomized multicenter, North American trial. Proc Am Soc Clin Oncol 1997;16:228a.
24.
Labianca R, Pancera G, Aitini E, Barni S, Beretta A, Beretta GD, Cesana B, Comella G, Cozzaglio L, Cristoni M, et al: Folinic acid + 5-fluorouracil (5-FU) versus equidose 5-FU in advanced colorectal cancer. Phase III study of ‘GISCAD’ (Italian Group for the Study of Digestive Tract Cancer). Ann Oncol 1991;2:673–679.
25.
Jäger E, Klein O, Bernhard H, Wächter B, Heike M, Theiss F, Dippold W, Meyer H, Knuth A: Weekly high-dose folinic acid (FA)/5-fluorouracil (FU) versus low-dose FA/FU in advanced colorectal cancer: results of a randomized multicenter trial. Proc Am Soc Clin Oncol 1994;13:192.
26.
Jäger E, Heike M, Bernhard H, Klein O, Bernhard G, Lautz D, Michaelis J, Meyer zum Buschenfelde KH, Knuth A: Weekly high-dose leucovorin versus low-dose leucovorin combined with fluorouracil in advanced colorectal cancer: results of a randomized multicenter trial. Study Group for Palliative Treatment of Metastatic Colorectal Cancer Study Protocol 1. J Clin Oncol 1996;14:2274–2279.
27.
Douillard JY, Cunningham D, Roth AD, Navarro M, James RD, Karasek P, Jandik P, Iveson T, Carmichael J, Alakl M, Gruia G, Awad L, Rougier P: Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet 2000;355:1041–1047.
28.
Goldberg RM, Morton RF, Sargent DJ, Fuchs C, Ramanathan RK, Williamson SK, Findlay BP: N9741: oxaliplatin (Oxal) or CPT-11 + 5-fluorouracil (5FU)/leucovorin (LV) or oxal + CPT-11 in advanced colorectal cancer (CRC). Updated efficacy and quality of life (QOL) data from an intergroup study. Proc Am Soc Clin Oncol 2003;22:252.
29.
De Gramont A, Figer A, Seymour M, Homerin M, Hmissi A, Cassidy J, Boni C, Cortes Funes H, Cervantes A, Freyer G, Papamichael D, Le Bail N, Louvet C, Hendler D, De Braud F, Wilson C, Morvan F, Bonetti A: Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 2000;18:2938–2947.
30.
Seymour M, on behalf of the NCRI Colorectal Group: Optimizing the use and sequencing of fluorouracil, irinotecan and oxaliplatin in advanced colorectal cancer (ACRC): The UK MRC FOCUS (CR08) trial. Ann Oncol 2004;15(suppl 3):2–3.
© 2006 S. Karger AG, Basel
2006
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.